论文部分内容阅读
为了测试非皮肤癣菌性霉菌在人体角质层内的生长状况 ,测试伊曲康唑抗病原性非皮肤癣菌性霉菌的活性 ,取健康志愿者和正在接受伊曲康唑 2 0 0mg/d治疗至少 2周的患者的皮肤角质层 ,选黄曲霉菌、尖孢镰刀菌、短帚霉菌和暗色柱顶孢霉菌作为试验菌种 ,用角质层真菌计量分析法进行研究。发现在 1周内 ,健康者的角质层样本中均有真菌菌丝体生长 ,但受试的不同霉菌其生长状态和发育程度有很大的差异。在含有伊曲康唑的角质层样本中真菌生长受到抑制 ,伊曲康唑的抗真菌活性的水平比常规的最小抑菌浓度所示的抗真菌活性要高。结论 :一些重要的病原性非皮肤癣菌性霉菌能通过形成菌丝的方式在人体角质层中生长 ;但其生长过程有部分被角质层自身的一些不明机制所抑制 ,而且被口服的伊曲康唑进一步抑制。
To test the growth of non-dermatophyte molds in the human stratum corneum, the activity of itraconazole against pathogenic non-dermatophyte molds was tested, healthy volunteers and those receiving itraconazole at 200 mg / d Skin stratum corneum in patients treated for at least 2 weeks, selected from Aspergillus flavus, Fusarium oxysporum, Groom’s fungus, and Acremonium subtilis as test strains, were studied using stratum fungi metrological analysis. Found within 1 week, the health of the stratum corneum samples are fungal mycelium growth, but the test of different mold growth state and degree of development are very different. Fungal growth is inhibited in the cuticle samples containing itraconazole, and the antifungal activity of itraconazole is higher than the antifungal activity indicated by the conventional minimum inhibitory concentration. CONCLUSIONS: Some important pathogenic non-dermatophyte molds can grow in the human stratum corneum through the formation of mycelium; however, some of their growth is inhibited by some unknown mechanisms of the stratum corneum itself and is orally administered Conazole further inhibits.